Document is current

Article History

Accepted: 26 April 2022

First Online: 17 June 2022

Declarations

:

: The study was funded by F. Hoffmann-La Roche Ltd/Genentech, Inc.

: TT reports consultancy fees from F. Hoffmann-La Roche Ltd. HT reports lecture fees from AstraZeneca and Roche. SG reports personal fees from Bayer, EUSA Pharma, and LOXO Oncology. CR reports personal fees from Amgen, BMS, Celgene, Genentech, Inc., Novartis, Pfizer, and F. Hoffmann-La Roche Ltd. DP was an employee of F. Hoffman-La Roche Ltd. at the time of study conduct. LM was an employee of Genentech, Inc. at the time of study conduct. LRP is an employee of F. Hoffmann-La Roche Ltd. SC, KEH, CD, and RB are employees of and stock-holders in F. Hoffmann-La Roche Ltd/Genentech, Inc. All other authors declare no competing interests.

: This study was performed in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

: Written informed consent was obtained from parents, patients, or legal representatives.

: Not applicable.

: Qualified researchers may request access to individual patient level data through the clinical study data request platform (). Further details on Roche's criteria for eligible studies are available here (). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here ().

: Not applicable.

: TT and BG contributed to the conception and design of the study. All authors contributed to collection and assembly of data, and to data analysis and interpretation. All authors critically reviewed the manuscript, provided final approval, and agreed to be accountable for all aspects of the work.